Analysts predict increased losses per share for next year and lower revenue estimates. The consensus price target fell, indicating greater pessimism about the company's intrinsic value. The company's revenue growth is expected to slow significantly, lagging behind the wider industry.
Tonyco : $ブルーバード・バイオ (BLUE.US)$
$X4ファーマシューティカルズ (XFOR.US)$
$エディブル・ガーデンAG (EDBL.US)$